Arvinas ARVN
NASDAQ ARVN
$7.59 +0.04 (+0.46%)
As of: Oct 22, 2026 · 12:00 PM EDT

Arvinas (ARVN) Total Non-Current Liabilities (2018)

Updated

Arvinas (ARVN) reported Total Non-Current Liabilities of $62.53 million for Q4 2018.

Analysis

Arvinas (ARVN) Total Non-Current Liabilities (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,170.64 Bn 1,139.22 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 640.54 Bn 559.06 Bn 17.26 Bn 105.50 Bn
3 AbbVie 501.78 Bn 474.89 Bn 12.70 Bn 106.45 Bn
4 Merck 374.95 Bn 329.32 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 302.43 Bn 266.42 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 268.31 Bn 241.99 Bn 12.86 Bn 33.91 Bn
7 Amgen 242.70 Bn 198.10 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 193.64 Bn 167.84 Bn 6.22 Bn 35.10 Bn
9 Pfizer 172.34 Bn 118.98 Bn 10.94 Bn 97.04 Bn
10 Arvinas 491.83 Mn -2.16 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 62.53 Mn
API Access

Arvinas Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=ARVN&period=max&api_key=YOUR_API_KEY